I find it hard to believe there won't be multiple interested parties for:
bisPSMA construct, which has nearly proven significantly higher uptake for diagnostics in their bcr combat trial
Cu64/67 pairing that is easily switched in their SAR cage, thus eliminating concerns of diagnostic/therapeutic targeting as well as keeping the payload specific to target.
Grpr targeting allowing for Bombesin and eventually breast
click tech antibody allowing for a massive potential platform
Sartate for GEP NET
I find it hard to believe there won't be multiple interested...
-
- There are more pages in this discussion • 209 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
